Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Influence of demographics and dosing on COVID-19 outcomes and Favipiravir efficacy

Wawman et al., Respiratory infections and bronchiectasis, doi:10.1183/13993003.congress-2024.PA1507, Sep 2024
https://c19early.org/wawman.html
Analysis of the Pioneer trial for favipiravir suggesting benefit in women and patients achieving target plasma concentrations. Only 17% of patients reached target plasma concentrations, with this subgroup showing trends toward improved outcomes (p=0.07 for primary endpoint, p=0.11 for mortality). The trial appears to have been significantly limited by inadequate dosing, with the vast majority of patients not reaching target drug concentrations.
Potential risks of favipiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-6.
Wawman et al., 14 Sep 2024, peer-reviewed, 11 authors.
DOI record: { "DOI": "10.1183/13993003.congress-2024.pa1507", "URL": "http://dx.doi.org/10.1183/13993003.congress-2024.PA1507", "alternative-id": [ "10.1183/13993003.congress-2024.PA1507" ], "author": [ { "affiliation": [], "family": "Wawman", "given": "Rebecca", "sequence": "first" }, { "affiliation": [], "family": "Orton", "given": "Christopher M", "sequence": "additional" }, { "affiliation": [], "family": "Boffito", "given": "Marta", "sequence": "additional" }, { "affiliation": [], "family": "Tana", "given": "Anand", "sequence": "additional" }, { "affiliation": [], "family": "Tonkin", "given": "James", "sequence": "additional" }, { "affiliation": [], "family": "Baikov", "given": "Alexandra N", "sequence": "additional" }, { "affiliation": [], "family": "Johnson", "given": "Mark R", "sequence": "additional" }, { "affiliation": [], "family": "Pozniak", "given": "Anton", "sequence": "additional" }, { "affiliation": [], "family": "Pelly", "given": "Michael", "sequence": "additional" }, { "affiliation": [], "family": "Bhavsar", "given": "Pankaj K", "sequence": "additional" }, { "affiliation": [], "family": "Shah", "given": "Pallav L", "sequence": "additional" } ], "container-title": "Respiratory infections and bronchiectasis", "content-domain": { "crossmark-restriction": true, "domain": [ "publications.ersnet.org" ] }, "created": { "date-parts": [ [ 2024, 11, 6 ] ], "date-time": "2024-11-06T19:11:33Z", "timestamp": 1730920293000 }, "deposited": { "date-parts": [ [ 2024, 11, 6 ] ], "date-time": "2024-11-06T19:11:33Z", "timestamp": 1730920293000 }, "event": "ERS Congress 2024 abstracts", "indexed": { "date-parts": [ [ 2024, 11, 6 ] ], "date-time": "2024-11-06T19:40:18Z", "timestamp": 1730922018541, "version": "3.28.0" }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 9, 14 ] ] }, "link": [ { "URL": "https://syndication.highwire.org/content/doi/10.1183/13993003.congress-2024.PA1507", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "81", "original-title": [], "page": "PA1507", "prefix": "10.1183", "published": { "date-parts": [ [ 2024, 9, 14 ] ] }, "published-online": { "date-parts": [ [ 2024, 10, 30 ] ] }, "published-print": { "date-parts": [ [ 2024, 9, 14 ] ] }, "publisher": "European Respiratory Society", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "http://publications.ersnet.org/lookup/doi/10.1183/13993003.congress-2024.PA1507" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Influence of demographics and dosing on COVID-19 outcomes and Favipiravir efficacy", "type": "proceedings-article", "update-policy": "http://dx.doi.org/10.1183/ers-crossmark-policy" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit